Tuesday night we held our June Monthly Conference Call, which Premium Members can access and rewatch here.
In this post, we’ll do our best to summarize it by highlighting five of the most important charts and/or themes we covered, along with commentary on each.
Something we've been working on internally is using various bottoms-up tools and scans to complement our top-down approach. It's really been working for us!
One way we're doing this is by identifying the strongest growth stocks as they climb the market-cap ladder from small- to mid- to large- and, ultimately, to mega-cap status (over $200B).
Once they graduate from small-cap to mid-cap status (over $2B), they come on our radar. Likewise, when they surpass the roughly $30B mark, they roll off our list.
But the scan doesn't just end there.
We only want to look at the strongest growth industries in the market, as that is typically where these potential 50-baggers come from.
The most significant transaction on today's list comes in a Form 4 filing by Matrix Capital Management.
The hedge fund reported the acquisition of 4,760,000 shares, equivalent to $107.8 million, in the small-cap biotech company Zentalis Pharmaceuticals, Inc $ZNTL.
